Reinforced Immunogenic Endoplasmic Reticulum Stress and Oxidative Stress via an Orchestrated Nanophotoinducer to Boost Cancer Photoimmunotherapy DOI
Zhenzhen Yang,

Yulu Teng,

Meng Lin

et al.

ACS Nano, Journal Year: 2024, Volume and Issue: 18(9), P. 7267 - 7286

Published: Feb. 21, 2024

Cancer progression and treatment-associated cellular stress impairs therapeutic outcome by inducing resistance. Endoplasmic reticulum (ER) is responsible for core events. Aberrant activation of sensors their downstream components to disrupt homeostasis have emerged as vital regulators tumor well response cancer therapy. Here, an orchestrated nanophotoinducer (ERsNP) results in specific ER-homing, induces hyperthermia mounting oxidative associated reactive oxygen species (ROS), provokes intense lethal ER upon near-infrared laser irradiation. The strengthened "dying" ROS subsequently induce apoptosis both primary abscopal B16F10 GL261 tumors, promote damage-associated molecular patterns evoke stress-dependent immunogenic cell death effects release "self-antigens". Thus, there a cascade activate maturation dendritic cells, reprogram myeloid-derived suppressor cells manipulate immunosuppression, recruit cytotoxic T lymphocytes effective antitumor response. long-term protection against recurrence realized through cascaded combinatorial preoperative postoperative photoimmunotherapy including the chemokine (C-C motif) receptor 2 antagonist, ERsNP irradiation, immune checkpoint inhibitor. highlight great promise exert potent reinforcing boost photoimmunotherapy.

Language: Английский

New opportunities and challenges of natural products research: When target identification meets single-cell multiomics DOI
Yuyu Zhu, Zijun Ouyang, Haojie Du

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2022, Volume and Issue: 12(11), P. 4011 - 4039

Published: Aug. 27, 2022

Language: Английский

Citations

246
Advances and challenges in the treatment of lung cancer DOI Open Access
Yuting Li,

Bingshuo Yan,

Shiming He

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 169, P. 115891 - 115891

Published: Nov. 16, 2023

Lung cancer accounts for a relatively high proportion of malignant tumors. As the most prevalent type lung cancer, non-small cell (NSCLC) is characterized by morbidity and mortality. Presently, arsenal treatment strategies encompasses surgical resection, chemotherapy, targeted therapy radiotherapy. However, despite these options, prognosis remains distressingly poor with low 5-year survival rate. Therefore, it urgent to pursue paradigm shift in methodologies. In recent years, advent sophisticated biotechnologies interdisciplinary integration has provided innovative approaches cancer. This article reviews cutting-edge developments nano drug delivery system, molecular photothermal strategy, immunotherapy Overall, systematically summarizing critically analyzing latest progress current challenges we aim provide theoretical basis development novel drugs treatment, thus improve therapeutic outcomes patients.

Language: Английский

Citations

139
Hot and cold tumors: Immunological features and the therapeutic strategies DOI Creative Commons
Lianjie Wang, Hui Geng, Yujie Liu

et al.

MedComm, Journal Year: 2023, Volume and Issue: 4(5)

Published: Aug. 26, 2023

Abstract The “hotness” or “coldness” of the tumors are determined by information cancer cells themselves, tumor immune characteristics, microenvironment, and signaling mechanisms, which key factors affecting patients’ clinical efficacy. switch mechanism its corresponding pathological characteristics treatment strategies frontier hot spot treatment. How to distinguish effectively clarify causes, microenvironment state, very important for response efficacy treatments. Starting from concept cold tumor, this review systematically summarized molecular influencing factors, therapeutic “hot tumors,” analyzed immunophenotypes, pathways, markers that contribute tumors” in details. Different “cold based on were with drug targets proteins tumors.” Furthermore, combines different traditional medicine modern medicine, provide a basis guidance decision‐making

Language: Английский

Citations

97
Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets DOI
Zhangfeng Zhong, Chi Teng Vong, Feiyu Chen

et al.

Medicinal Research Reviews, Journal Year: 2022, Volume and Issue: 42(3), P. 1246 - 1279

Published: Jan. 14, 2022

Abstract Immunotherapy sheds new light to cancer treatment and is satisfied by patients. However, immunotoxicity, single‐source antibodies, single‐targeting stratege are potential challenges the success of immunotherapy. A huge number promising lead compounds for natural origin from herbal medicines. The application products medicines that have immunomodulatory properties could alter landscape immunotherapy drastically. present study summarizes current medication discusses chemicals as immune checkpoint inhibitors a broad range effects. Therefore, this review provides valuable insights into efficacy mechanism actions immunotherapies, including combined with inhibitors, which confer an improved clinical outcome treatment.

Language: Английский

Citations

72
Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy DOI Creative Commons

Shuangneng Yin,

Zhaojun Chen, Dugang Chen

et al.

Theranostics, Journal Year: 2023, Volume and Issue: 13(5), P. 1520 - 1544

Published: Jan. 1, 2023

Immunotherapy has achieved great success recently and opened a new avenue for anti-tumor treatment. Programmed cell death 1/programmed ligand 1 (PD-1/PD-L1) are typical immune checkpoints that transmit coinhibitory signals, muting the host immunity. Monoclonal antibodies block PD-1/PD-L1 axis have benefited many patients with different tumor diseases. However, objective response rate is still unsatisfactory. In this review, we summarize three strategies targeting PD-L1 based on forms of various regulating mechanisms to enhance therapeutic effect, including blockade interaction between PD-1, downregulation expression degradation mature PD-L1. Thereinto, describe variety materials been designed target PD-L1, antibodies, nanoparticle, peptide, aptamer, RNA, small molecule. Additionally, list drugs regulation capacity used in clinical ongoing studies explore other alternatives besides anti-PD-L1 monoclonal antibodies. Moreover, discuss associated opportunities cancer combination therapy modalities such as chemotherapy, radiotherapy, photodynamic (PDT) photothermal (PTT), these conventional or emerging capable increasing cells by altering microenvironment (TME), would display synergistic effect. At last, give brief summary outlook regarding research status future prospect immunotherapy.

Language: Английский

Citations

62
Inhibition of inflammation by berberine: Molecular mechanism and network pharmacology analysis DOI
Kaijun Wang, Jie Yin, Jiayi Chen

et al.

Phytomedicine, Journal Year: 2024, Volume and Issue: 128, P. 155258 - 155258

Published: Jan. 11, 2024

Language: Английский

Citations

46
Herbal Therapies for Cancer Treatment: A Review of Phytotherapeutic Efficacy DOI Creative Commons
Andrej Jenča, David K. Mills,

Hadis Ghasemi

et al.

Biologics, Journal Year: 2024, Volume and Issue: Volume 18, P. 229 - 255

Published: Sept. 1, 2024

Natural products have proven to be promising anti-cancer agents due their diverse chemical structures and bioactivity.This review examines central role in cancer treatment, focusing on mechanisms of action therapeutic benefits.Medicinal plants contain bioactive compounds, such as flavonoids, alkaloids, terpenoids polyphenols, which exhibit various anticancer properties.These compounds induce apoptosis, inhibit cell proliferation cycle progression, interfere with microtubule formation, act topoisomerase targets, angiogenesis, modulate key signaling pathways, improve the tumor microenvironment, reverse drug resistance activate immune cells.Herbal drugs offer advantages, particularly selective toxicity against cells, reducing adverse side effects associated conventional chemotherapy.Recent studies clinical trials highlight benefits herbal medicines alleviating effects, improving tolerance chemotherapy occurrence synergistic treatments.For example, medicine SH003 was found safe potentially effective treatment solid cancers, while Fucoidan showed anti-inflammatory properties that are beneficial for patients advanced cancer.The current research landscape is extensive.Numerous investigating efficacy, safety cancers lung, prostate, breast hepatocellular carcinoma.Promising developments include polypharmacological approach, combination therapies, immunomodulation improvement quality life.However, there still challenges development use natural drugs, need further into action, possible interactions optimal dosage.Standardizing extracts, bioavailability delivery, overcoming regulatory acceptance hurdles critical issues addressed.Nonetheless, warrant investigation development.Multidisciplinary collaboration essential advance therapy integrate these mainstream treatment.

Language: Английский

Citations

16
Recent Advances in Small Molecule Inhibitors of Deubiquitinating Enzymes DOI

Pengwei Liu,

Zhengyang Chen,

Yiting Guo

et al.

European Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 117324 - 117324

Published: Jan. 1, 2025

Language: Английский

Citations

3
Tailoring traditional Chinese medicine in cancer therapy DOI Creative Commons

Shuiquan Li,

Xi Chen, Hui Shi

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: Jan. 21, 2025

Language: Английский

Citations

2
Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing DOI Creative Commons
Zhiru Wang,

Wen-Ting Kang,

Ouwen Li

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2020, Volume and Issue: 11(3), P. 694 - 707

Published: Nov. 16, 2020

Targeting immune checkpoints such as programmed cell death protein 1 (PD-1) and ligand-1 (PD-L1) have been approved for treating melanoma, gastric cancer (GC) bladder with clinical benefit. Nevertheless, many patients failed to respond anti-PD-1/PD-L1 treatment, so it is necessary seek an alternative strategy traditional PD-1/PD-L1 targeting immunotherapy. Here the data from The Cancer Genome Atlas (TCGA) our in-house tissue library, PD-L1 expression was found be positively correlated of ubiquitin-specific processing protease 7 (USP7) in GC. Furthermore, USP7 directly interacted order stabilize it, while abrogation attenuated PD-L1/PD-1 interaction sensitized cells T killing vitro vivo. Besides, inhibitor suppressed GC proliferation by stabilizing P53 Collectively, findings indicate that addition inhibiting proliferation, can also downregulate enhance anti-tumor response simultaneously. Hence, these posit anti-proliferation agent well a novel therapeutic blockade promote tumor.

Language: Английский

Citations

90